UX111 FDA approval date

The FDA approved UX111 (ABO-102) on 17 Sep 2026.

FDA approval date
17 Sep 2026

Drug identity checked against registry records

Also recorded as ABO-102; rebisufligene etisparvovec; scAAV9.U1a.hSGSH

Included trials

TrialSponsorPhaseStatusPrimary completion
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHNCT02716246RAREPhase 2, Phase 3Recruiting2029-03Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2026-09-17DayUX111Ultragenyx Pharmaceutical Inc · RAREFDA CBER biologic approvalFDA approval decisionIndicated for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo Syndrome type A) in pediatric patients with preserved neurodevelopmental function.Open original source
Read source excerpt

{"product": "Fayuvi rebisufligene etisparvovec-hopf", "indication": "Indicated for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo Syndrome type A) in pediatric patients with preserved neurodevelopmental function.", "application": "125845/0", "manufacturer": "Ultragenyx Pharmaceutical Inc.", "date": "2026-09-17"}

First seen: 03 Nov 2026 · Evidence last checked: 03 Nov 2026